Nurix, Gilead extend research term for oncology program by two years for $10 million fee

By Public Technologies
  • Nurix Therapeutics extended the research term for an undisclosed oncology program under its strategic collaboration with Gilead by two years.
  • Extension marks the second two-year renewal for the program under the 2019 agreement.
  • Nurix will receive a USD 10 million research term extension fee under the amended deal.
  • Nurix can opt into co-development with 50/50 US profit-sharing on up to two programs, subject to restrictions.
  • Deal economics include potential payments of up to about USD 1.3 billion, tied to fees and milestone events.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nurix Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050700PRIMZONEFULLFEED9838803) on October 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.